About
AlzWIN is an AI-based voice tool that detects cognitive decline in 1 minute using verbal fluency. Validated by trials, peer-reviewed, patented, FDA Class II registered, and ISO/GMP certified, it has flagged over 10,200 high-risk dementia cases and is backed by clinics, insurers, and pharma leaders.
Founders Bio
The founder leads Seven Point One, advancing AI/XR healthcare for aging populations. They created AlzWIN (AI dementia screening, FDA Class II) and SENTENTS (XR mental/physical therapy), both award-winning innovations. A former VP at MEMEBOX ($150M+ raised), ex-BAML investment banker, and Republic of Korea Air Force officer, they bring deep expertise in finance, diplomacy, and health innovation.
Origin Story
AlzWIN began after a family member’s late dementia diagnosis. Motivated by the belief that digital tools could help, a multidisciplinary team was formed to develop the most accessible voice-based screening tool for early detection. The mission extends beyond diagnosis—to build a collaborative ecosystem for aging care that benefits patients, families, and healthcare systems alike.
Honors and Awards
- Roche Diagnostics Global Expansion Partner Demoday – Winner: Recognized as a top digital health solution for global growth.
- Open Innovation Partner – Eisai: Selected for collaboration with pharmaceutical leader Eisai on dementia innovation.
- CES Innovation Awards 2023 – Honoree: Honored for groundbreaking AI-powered dementia screening tool, AlzWIN.
- Presidential Commendation – South Korea: Awarded for national contributions to healthcare innovation.